Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC)

World Journal of Urology

Volumn 32, Issue 5, 2014, Pages 1281-1285

  Shindo, Tetsuya ^a   Masumori, Naoya ^a   Kitamura, Hiroshi ^a   Tanaka, Toshiaki ^a   Fukuta, Fumimasa ^a   Hasegawa, Tadashi ^a   Yanase, Masahiro ^b   Miyake, Masafumi ^c   Miyao, Noriomi ^d   Takahashi, Atsushi ^e   Matsukawa, Masanori ^f   Taguchi, Keisuke ^g   Shigyo, Masanori ^h   Kunishima, Yasuharu ⁱ   Tachiki, Hitoshi ^j   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SUNAGAWA CITY MEDICAL CENTER   (Japan)

^c ASAHIKAWA RED CROSS HOSPITAL   (Japan)

^d Muroran City General Hospital   (Japan)

^e HAKODATE GORYOUKAKU HOSPITAL   (Japan)

^f KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^g Oji General Hospital   (Japan)

^h Kushiro Red Cross Hospital   (Japan)

ⁱ Obihiro Hospital   (Japan)

^j Steel Memorial Muroran Hospital   (Japan)

more..

Author keywords

Bladder cancer; Muscle layer; Progression rate; T1G3

Indexed keywords

EID: 84886733921     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-013-1205-1     Document Type: Article

References (14)

1. Dutta SC, Smith JA Jr, Shappell SB et al (2001) Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166:490–493
2. Shahin O, Thalmann GN, Rentsch C et al (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette–Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169:96–100
3. Denzinger S, Otto W, Fritsche HM et al (2007) Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol 14:995–999
4. Moonen PMJ, Balken-Ory B, Kiemeney LALM et al (2007) Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 177:80–83
5. Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666–675
6. Shindo T, Masumori N, Fukuta F et al (2010) Is T1G3 bladder cancer having a definite muscle layer in TUR specimens a highly progressive disease? Jpn J Clin Oncol 40:153–156
7. Kulkarmi GS, Hakenberg OW, Gschwend JE et al (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57:60–70
8. Sylvester RJ, Meijden A, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477
9. Gohji K, Nomi M, Okamoto M et al (1999) Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 53:308–313
10. Park J, Song C, Hong JH et al (2009) Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer. World J Urol 27:277–283
11. Mariappan P, Zachou A, Grigor KM (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57:843–849
12. Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162:74–76
13. Kim W, Song C, Park S et al (2012) Value of immediate second resection of tumor bed to improve the effectiveness of transurethral resection of bladder tumor. J Endourol 26:1059–1064
14. Divrik RT, Sahin AF, Yildirim U et al (2010) Impact of routine second transurethral resection on the long term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomized clinical trial. Eur Urol 58:185–190